A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients'. Together they form a unique fingerprint.

Medicine & Life Sciences